Which products require nitrosamine testing?

Author : mahek dangi | Published On : 07 Nov 2026

Nitrosamine testing is required for pharmaceutical products where a risk assessment identifies possible nitrosamine formation or cross-contamination. This can include APIs and finished medicines containing amine groups, nitrites in excipients, recovered solvents, certain reagents, or packaging materials that may contribute to nitrosamine formation. Products such as sartans, metformin, rifampicin, rifapentine, ranitidine and varenicline have previously required regulatory attention.

If a product is considered at risk, manufacturers should perform nitrosamine analysis, sensitive nitrosamine detection, and confirmatory nitrosamine testing using properly validated methods. Testing is risk-based; it is not automatically required for every medicine when a supported assessment shows no credible risk.

Molkem provides reliable nitrosamine analysis services for APIs, finished drug products, excipients and intermediates. Its support includes risk evaluation, method development, validation and confirmatory nitrosamine analytical testing against applicable acceptable intake limits. 

Conclusion: Products with an identified risk of nitrosamine formation or contamination require confirmatory testing. A product-specific risk assessment should always determine the exact testing requirement.